Genmab: Epkinly Shines In Phase 3 DLBCL Trial (NASDAQ:GMAB)
· seekingalpha.com
Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Click for more on GMAB stock.
I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signi...